Is Nuwellis going out of business?

Nuwellis, Inc. (NUWE) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Nuwellis, Inc. (NUWE) scores 16 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)

Five questions, kept separate

Survival - Critical

3-5 mo of estimated runway from 2026-06-30, based on $3.9M of cash and short-term investments against $10.9M of annual burn.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Demanding

15.1% net-cash backing support a demanding pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)
• FCF margin: -131.80%
• Cash Runway (years): 0.36y
• Revenue CAGR (3Y): -1.08%
• R&D intensity: 39.58%
• Return on Assets: -191.99%
• Revenue growth YoY: 14.14% (YoY)
• Shares dilution YoY: -22.41% (YoY)
• Cash Burn Deceleration: -145.71% QoQ improvement (Worsening)
• Revenue Quality: Quality concerns (DSO +16d, Rev +14%)
• Price / Sales: 0.3x (see Valuation)
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-08-13.

Price as of 2026-09-07.